Consensus BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq 21:00:00 12/07/2024 BST 5-day change 1st Jan Change
152.2 USD +1.11% Intraday chart for BeiGene, Ltd. +3.49% -15.63%

Evolution of the average Target Price on BeiGene, Ltd.

Price target over the last 5 years

History of analyst recommendation changes

ad137b6a12555e8e0633f3f47c.mS0SUiDERS_1qdeTodKlKf0x-ZTRgvJQ_r5vkmwoSCc.8ltCf1P3AFyh7YflzeGQQcoGwMCBy6RlkOEizStCEnfteFYaF6gqQYLu4w~7d5b426c60f35a3becdca9b6e250e57e
Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing MT
Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing MT
Beigene Issues Shares Under Incentive Schemes MT
BeiGene to Award Shares Worth $15 Million to 11 Directors MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating MT
Nomura Adjusts Beigene’s Price Target to HK$150.60 From HK$162.05, Keeps at Buy MT
Nomura Adjusts BeiGene Price Target to $268.36 From $253.14, Maintains Buy Rating MT
Citigroup Lowers Price Target on BeiGene to $285 From $290, Maintains Buy Rating MT
Citigroup Raises BeiGene Price Target to $290 From $285, Maintains Buy Rating MT
Macquarie Starts BeiGene at Outperform, $259 Price Target MT
Morgan Stanley Adjusts BeiGene's Price Target to $319 From $321, Keeps Overweight Rating MT
Jefferies Starts BeiGene at Buy With $287 Price Target MT
JPMorgan Chase Adjusts Price Target on BeiGene to $300 From $297, Maintains Overweight Rating MT
Nomura Adjusts BeiGene Price Target to $253.14 From $309.47, Maintains Buy Rating MT
Nomura Adjusts BeiGene's Price Target to HK$152.86 From HK$186.87, Keeps at Buy MT
Citigroup Initiates BeiGene With Buy Rating, $275 Price Target MT
Bernstein Downgrades BeiGene to Market Perform From Outperform, Cuts Price Target to $196 From $335 MT
Nomura Adjusts BeiGene's Price Target to HK$186.87 From HK$172.81, Keeps at Buy MT
Nomura Adjusts BeiGene Price Target to $309.47 From $286.19, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on BeiGene to $321 From $325, Maintains Overweight Rating MT
Cowen Adjusts Price Target on BeiGene to $262 From $213, Maintains Outperform Rating MT
Nomura Adjusts BeiGene's Price Target to $286.19 From $281.78, Maintains Buy Rating MT
Nomura Adjusts BeiGene's Price Target to HK$172.81 From HK$170.15, Keeps at Buy MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
152.2 USD
Average target price
263 USD
Spread / Average Target
+72.83%
High Price Target
345 USD
Spread / Highest target
+126.72%
Low Price Target
152 USD
Spread / Lowest Target
-0.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BeiGene, Ltd.

Bernstein
Nomura
Citigroup
Macquarie
Morgan Stanley
Jefferies & Co.
JPMorgan Chase
Cowen
SVB Securities LLC
Guggenheim
CMB International
SVB Leerink
Goldman Sachs
HSBC
China Renaissance
CLSA
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. Consensus BeiGene, Ltd.